Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABK-KRAS-1
- Development stage
- Preclinical
- Lead developer
- Abbisko Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABK-KRAS-1 is an orally available, small-molecule inhibitor that targets a broad spectrum of KRAS mutations (pan-KRAS inhibitor). It has demonstrated potent in vitro activity against various KRAS mutant forms and induces dose-dependent tumor regression in preclinical xenograft models. The drug is being developed as a promising therapeutic candidate for the treatment of cancers harboring KRAS mutations, which are common drivers in multiple solid tumors. ABK-KRAS-1 exhibits favorable drug-like properties and is currently at the preclinical development stage. The developer is Abbisko Therapeutics.
- Other names
- pan-KRAS inhibitor
02
Targets
Beyond the preview
Go deeper on ABK-KRAS-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABK-KRAS-1.